Mankind Pharma Ltd

- Mankind Pharma raised INR10,000 crores through NCDs and CPs for the acquisition of BSV. - Additionally, INR3,000 crores was raised via equity and used to repay a portion of CPs as of January 16, 2025. - There was no mention of any new or upcoming fundraising plans through debt or equity in the latest call. - The company emphasized maintaining a healthy financial position with a focus on reducing net debt to adjusted EBITDA to 2x by year-end. - Current net debt to adjusted EBITDA stands at 2.2x as of the quarter-end. - No explicit plans for fresh fundraising were disclosed; focus remains on integration, corrective actions, and financial discipline.

- Capex spends for 9M FY'25 were INR344 crores, which is 3.7% of total revenue, aligning with guidance of 4%-5%. - Strategic investments include the acquisition of BSV to expand into high entry barrier portfolios and specialty R&D tech platforms. - The company raised INR10,000 crores through NCDs and CPs for the BSV acquisition and INR3,000 crores in equity used to repay CPs, showing financial discipline. - Future investments include ongoing R&D initiatives to enter semi-regulated and regulated markets, supporting margin improvement in BSV business. - Integration and synergies from the BSV acquisition (expected INR50-100 crores benefit over 12-24 months) involve procurement optimization, portfolio rationalization, field force productivity, and cross-selling opportunities. - Capex guidance remains around 4%-5% of revenue, indicating continued focus on capital investments for growth.

- Mankind Pharma aims for sustainable long-term growth, focusing on solid foundations and efficiency improvements. - Organic domestic growth is expected to continue, with Q3 FY25 showing 8.4% domestic growth and 43% export growth. - Chronic segment is growing faster and gaining share, currently at 37.6% of sales, up 200 bps YoY. - BSV business integration is underway with expectations of a flat to single-digit growth in FY25; post restructuring, growth should recover. - The company targets 15%+ growth for BSV portfolio over the next two years, driven by high entry barriers and specialty products. - Margins are expected to improve gradually by about 100 bps annually over the next 2-3 years, aiming for 30% margins in BSV. - Corrective measures in field force and leadership reshuffling are ongoing to drive productivity, with most changes nearing completion.

- BSV business margins expected to improve by ~100 bps annually over next 2-3 years, targeting 30% margins in 5 years. - EBITDA margins have increased due to corrective actions and are expected to sustain improvements. - Corrective actions in field force and management led to improved efficiency, margins, and foundation for growth despite short-term growth impact. - Organic domestic and export growth remain strong, with export growing 43% YoY in Q3 FY25 and 53% in 9M FY25. - Chronic segment growing faster than acute, with chronic share rising to 37.6% of total sales, driving better profitability. - Net debt to adjusted EBITDA target set at 2x by year-end to maintain financial discipline. - Long-term vision includes steady base business, fast-growing specialty chronic segment, OTC expansion, and high entry barrier super-specialty portfolio driving sustainable earnings growth. - Corrective actions and new leadership infusion expected to support consistent margin improvement and EPS growth.

The transcript provided from Mankind Pharma Limited's Q3 & 9M FY25 earnings call does not explicitly mention any details regarding current or expected order book or pending orders. The discussion focuses mainly on financial performance, operational efficiencies, integration of BSV business, market growth, leadership changes, and strategic initiatives. There is no specific information on order backlog or pending orders mentioned on page 18 or in surrounding pages of the transcript.